Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients

BACKGROUND: There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M‐cis‐C797S. The aim of this study was to investigate the association between different therapeutic strategies and survival outcomes among these pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yaning, Xu, Haiyan, Ma, Li, Yang, Lu, Yang, Guangjian, Zhang, Shuyang, Ai, Xin, Zhang, Shucai, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633234/
https://www.ncbi.nlm.nih.gov/pubmed/34612594
http://dx.doi.org/10.1002/cam4.4336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633234/
https://www.ncbi.nlm.nih.gov/pubmed/34612594
http://dx.doi.org/10.1002/cam4.4336

Ejemplares similares